Efficacy and safety of sorafenib in patients with advanced clear-cell renal-cell carcinoma (RCC) with bone metastases: results from the phase III TARGET study

被引：0

作者：

Gschwend, J. E. ^{[1
]}

Bukowski, R. ^{[2
]}

Eisen, T. ^{[3
]}

Stadler, W. S. ^{[4
]}

Szczylik, C. S. ^{[5
]}

Oudard, O. S. ^{[6
]}

Siebels, M. S. ^{[7
]}

Michel, M. S. ^{[8
]}

Grimm, M. O. ^{[9
]}

Escudier, B. E. ^{[10
]}

机构：

[1] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin & Poliklin, Munich, Germany

[2] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA

[3] Cambridge Res Inst, Cambridge, England

[4] Univ Chicago, Chicago, IL 60637 USA

[5] Mil Med Acad, Warsaw, Poland

[6] Hop Euopeen Georges Pompidou, Paris, France

[7] LMU, Klinikum Grosshadern, Munich, Germany

[8] Univ Klinikum Mannheim, Mannheim, Germany

[9] Klinikum Carl Gustav Carus, Dresden, Germany

[10] Inst Gustave Roussy, Villejuif, France

来源：

ONKOLOGIE | 2010年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：130 / 131

页数：2

共 50 条

[1] Efficacy and safety of sorafenib in patients with advanced clear-cell renal-cell carcinoma (RCC) with bone metastases: results from the phase III target study
Bukowski, R.
Eisen, T. E.
Stadler, W. S.
Szczylik, C. S.
Oudard, O. S.
Siebels, M. S.
Negrier, S. N.
Anderson, S. A.
Shan, M. S.
Escudier, B. E.
EJC SUPPLEMENTS, 2009, 7 (02): : 432 - 432
[2] Efficacy and safety of sorafenib in patients with advanced clear-cell renal cell carcinoma (RCC) with diabetes: Results from the phase III TARGET study
Oudard, S.
Eisen, T.
Szczylik, C.
Siebels, M.
Negrier, S.
Chevreau, C.
Cihon, F.
Bukowski, R. M.
Escudier, B.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[3] Sorafenib in advanced clear-cell renal-cell carcinoma
Escudier, Bernard
Eisen, Tim
Stadler, Walter M.
Szczylik, Cezary
Oudard, Stephane
Siebels, Michael
Negrier, Sylvie
Chevreau, Christine
Solska, Ewa
Desai, Apurva A.
Rolland, Frederic
Demkow, Tomasz
Hutson, Thomas E.
Gore, Martin
Freeman, Scott
Schwartz, Brian
Shan, Minghua
Simantov, Ronit
Bukowski, Ronald M.
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02): : 125 - 134
[4] Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET study
Hutson, T. E.
Bellmunt, J.
Porta, C.
Staehler, M.
Szczylik, C.
Nadel, A.
Anderson, S.
Bukowski, R. M.
Eisen, T.
Escudier, B.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[5] Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview
Hutson, Thomas E.
EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (09) : 1193 - 1202
[6] Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib
Zimmermann, Kaja
Schmittel, Alexander
Steiner, Ursula
Asemissen, Anne Marie
Knoedler, Maren
Thiel, Eckhard
Miller, Kurt
Keilholz, Ulrich
ONCOLOGY, 2009, 76 (05) : 350 - 354
[7] Re: Sorafenib in advanced clear-cell renal cell carcinoma
Karakiewicz, Pierre I.
Hutterer, Georg
EUROPEAN UROLOGY, 2007, 52 (01) : 279 - 280
[8] Sorafenib in advanced clear-cell renal-cell carcinoma (vol 356, pg 125, 2007)
Escudier, Bernard
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (02): : 203 - 203
[9] Sorafenib in advanced renal cell carcinoma (RCC): Survival and biomarker results from a phase III trial
Bukowski, R.
Hong, D.
Eisen, T.
Szczylik, C.
Stadler, W. M.
Porte, C.
Simantov, R.
Shan, M.
Elting, J.
Pena, C.
Escudier, B.
EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 245 - 245
[10] Safety and efficacy of sorafenib in patients with advanced renal cell carcinoma (RCC) with varying histologies: results from the phase 3, open access study of sorafenib in European patients with advanced RCC (EU-ARCCS)
Keilholz, U.
Gore, M.
Bracarda, I
Richel, N.
Staehler, M.
von der Maase, H.
Stierner, U.
Strauss, U. P.
Porta, C.
Bokemeyer, C.
ONKOLOGIE, 2010, 33 : 130 - 130

← 1 2 3 4 5 →